Arbaclofen placarbil
XenoPort has discontinued its potential spasticity treatment (a slow release version of baclofen) after a phase 3 trail showed it was no more effective than placebo.
Reuters
Spacticity - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news